antimony has been researched along with Granulocytic Leukemia, Chronic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kneifel, C; Lösler, S; Rojewski, MT; Schlief, S; Schrezenmeier, H; Thiel, E | 1 |
1 other study(ies) available for antimony and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
Topics: Antimony; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine Sulfoximine; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Glutathione; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Membrane Potential, Mitochondrial; Neoplasm Proteins; Oxidation-Reduction; Oxides | 2009 |